Clinical trials: Hepatitis B， Chronic
Chronic Hepatitis B
Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B
Background: Hepatitis B is a viral infection of the liver. When the immune system tries to clear hepatitis B, it damages the liver. Eventually, the immune system gets exhausted fighting the virus.
- Trial name
- NCT03575208
- Testing
- hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN)
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B
Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
This is a prospective, randomized, multicenter, open-label study. After more than 24 weeks NA treatment, HBeAg positive CHB patients who achieved HBV DNA<1000copies/ml but HBeAb negative, will be randomized (1:1) into 2 study…
- Trial name
- NCT02474316
- Testing
- Peginterferon alfa-2a, nucleos(t)ide analgoue
- Where
- 3 sites in China
- Volunteers
- 366 people
- Sponsor
- Ruijin Hospital
Chronic Hepatitis b
Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B
BACKGROUND: Finite nucleos(t)ide analogue (Nuc) therapy was proposed as an alternative strategy in the management of chronic hepatitis B (CHB) but there remained not data from randomized controlled trials to clarify safety and…
- Trial name
- NCT05793268
- Testing
- Nuc Discontinuation, Entecavir or Tenofovir
- Where
- 6 sites in Taiwan
- Volunteers
- 360 people
- Sponsor
- E-DA Hospital
HBV Infection With LLV
Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection
This study is a phase II multicenter, randomized, double-blind, placebo controlled study designed to evaluate the efficacy and safety in LLV subjects and demonstrate that TQA3605 tablets combined with oral NAs drugs can improve…
- Trial name
- NCT06644417
- Testing
- TQA3605 tablets plus NAs
- Where
- 19 sites in China
- Volunteers
- 122 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B Virus, HBV
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.
- Trial name
- NCT01438424
- Testing
- Entecavir, Lamivudine
- Volunteers
- 1,053 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis b
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects
A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects.
- Trial name
- XT1061 (NCT06280534)
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Chronic Hepatitis B
NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients
The general objective of the present clinical trial is to compare the therapeutic efficacy of a combination therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) [later called…
- Trial name
- NASVAC (NCT01374308)
- Testing
- NASVAC, Pegylated interferon alpha 2b
- Where
- Bangladesh
- Volunteers
- 160 people
- Sponsor
- Clinical Research Organization, Dhaka, Bangladesh
Hepatocellular Carcinoma
Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients
The goal of this study is Utility of abbrevational magnetic resonance imaging as a screening tool for hepatocellular carcinoma in cirrhotic patients.
- Trial name
- NCT05716620
- Testing
- MRI
- Where
- India
- Volunteers
- 380 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis B, Chronic, Virus Diseases
Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory
Refractory hepatitis B is to point to although standard application nucleoside (acid) analogue treatment undertakes primary treatment and two strengthen treatment, but existence is persistent viremia.
- Trial name
- NCT05376124
- Testing
- original therapy, rescue therapy
- Where
- 13 sites in China
- Volunteers
- 110 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Safety Issues, Chronic Hepatitis B
Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver transplant patients with chronic HBV infection.
- Conditions
- Safety Issues, Chronic Hepatitis B, Transplant Recipient
- Trial name
- NCT05410496
- Testing
- Tenofovir Alafenamide 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 52 people
- Sponsor
- Taichung Veterans General Hospital
Chronic Hepatitis B
Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients
The World Health Organization (WHO) has set a target to eliminate viral hepatitis by 2030, aiming for a 90% diagnosis rate and an 80% treatment rate for chronic hepatitis B (CHB).
- Trial name
- Union-FAST (NCT07520123)
- Testing
- Agent Intelligence education
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatitis B, Chronic
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).
- Trial name
- ASPIRE-202 (NCT07654283)
- Testing
- AHB-137
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- AusperBio Therapeutics Inc.
Chronic Hepatitis B
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus…
- Trial name
- NCT04398134
- Testing
- ABI-H2158, Entecavir (ETV)
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 88 people
- Sponsor
- Assembly Biosciences
Chronic Hepatitis B
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
The purpose of this study is to evaluate the efficacy and safety following the Roadmap Concept strategy with an initial monotherapy using either telbivudine or tenofovir in HBeAg negative CHB patients.
- Trial name
- NCT01379508
- Testing
- telbivudine, tenofovir disoproxil fumarate
- Where
- 34 sites in Austria, Bulgaria and 6 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
The presence of persistent inadequate or suboptimal virologic response is a strong risk factor for viral resistance and breakthrough and also for disease progression of chronic hepatitis B, and thus, a change in therapy is…
- Trial name
- CAESAR (NCT01023217)
- Testing
- Adefovir, Entecavir, Lamivudine
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma, Hepatitis B
Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population
Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC), imposing a significant health and economic burden globally.
- Trial name
- NCT06379334
- Testing
- Urine test
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Chronic Hepatitis B, Sonoelastography
Evaluation of Liver Fibrosis With 2D-Shear Wave Elastography
The aims of this study are to evaluate liver fibrosis with two-dimensional (2D) shear wave elastography (SWE) technique in inactive hepatitis B surface antigen (HBsAg) carriers and patients with active chronic hepatitis B (CHB)…
- Conditions
- Chronic Hepatitis B, Sonoelastography, Fibrosis, Liver
- Trial name
- NCT04759521
- Where
- Turkey (Türkiye)
- Volunteers
- 253 people
- Sponsor
- Seyhmus Kavak
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV).
- Trial name
- NCT00436163
- Testing
- Peginterferon alfa-2a
- Where
- 9 sites in Estonia, Latvia and 1 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability…
- Trial name
- NCT04412863
- Testing
- VIR-2218, pegylated interferon-alfa 2a
- Where
- 22 sites in Australia, Hong Kong and 4 more
- Volunteers
- 84 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Hepatitis B
Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
The aim is to investigate whether Lamivudine 100mg daily is effective in the long term treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia
- Trial name
- NCT00338780
- Where
- China
- Sponsor
- Chinese University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.